- Poster presentation
- Open Access
PReS-FINAL-2342: Anti-TNFALPHA therapy targeys PKB/C-AKT induced resistance of effector cells to suppression in juvenile arthritis
© Wehrens et al.; licensee BioMed Central Ltd. 2013
- Published: 5 December 2013
- Synovial Fluid
- Juvenile Idiopathic Arthritis
- Effector Cell
Resistance of effector T cells (Teff) to suppression contributes to disturbed immune regulation in autoimmune disease. Targeting this unresponsiveness to suppression might therefore have beneficial effects in autoimmune inflammation. In juvenile idiopathic arthritis (JIA) we have recently shown that Teff from inflamed joints are refractory to suppression, which was associated with enhanced PKB/c-akt activation in these cells.
To investigate whether anti-IL-6 and anti-TNFα target unresponsiveness of Teff to suppression in patients with JIA.
Resistant Teff from the inflamed joints of JIA patients were cultured in the presence of etanercept or anti-IL-6 in vitro and PKB/c-akt activation and responsiveness to suppression was measured. In addition, in vivo effects of TNFα blockade were investigated using peripheral blood samples of patient before and after start of etanercept therapy.
In vitro treatment of synovial fluid Teff with anti-IL-6 led to improved Treg mediated suppression of cell proliferation in some, but not all patients. Blocking TNFα with etanercept however clearly enhanced suppression in all samples analyzed. In the presence of etanercept PKB/c-akt activation of Teff was reduced and Teff became more susceptible to TGFβ-mediated suppression, indicating that anti-TNFα directly targets resistant Teff.
This study is the first to show resistance of Teff to suppression as a target of anti-TNFα therapy in arthritis, resulting in improved regulation of inflammatory effector cells.
E. Wehrens: None Declared, S. Vastert Consultant for: novartis < 1000 euros, G. Mijnheer: None Declared, J. Meerding: None Declared, M. Klein: None Declared, N. Wulffraat Grant/Research Support from: Abbvie, Roche, Consultant for: Novartis, Pfizer, B. Prakken: None Declared, F. van Wijk: None Declared.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.